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Abstract 25 
Primary aldosteronism encompasses two major underlying causes: (1) aldosterone producing 26 
adenoma and (2) bilateral adrenal hyperplasia. In addition to the aldosterone excess, increased 27 
production of other compounds of the steroidogenic pathways may be involved. Until recently, 28 
most studies examined the production of steroids other than aldosterone in tumor tissue, urine or 29 
peripheral plasma samples but several new studies have also addressed steroid levels in adrenal 30 
venous blood samples using liquid chromatography tandem mass spectrometry. Plasma and tissue 31 
levels of several precursors of aldosterone with mineralocorticoid activity are higher in patients 32 
with aldosterone producing adenomas than in those with bilateral hyperplasia. These include 33 
corticosterone, deoxycorticosterone and their 18-hydroxylated metabolites. Similarly, urinary, 34 
peripheral and adrenal venous concentrations of the hybrid steroids 18-oxocortisol and 18-35 
hydroxycortisol are higher in patients with aldosterone producing adenomas than in bilateral 36 
hyperplasia.  37 
Differences in the pathophysiology and in clinical and biochemical phenotypes caused by 38 
aldosterone producing adenomas and bilateral adrenal hyperplasia may be related to the 39 
differential expression of steroidogenic enzymes, and associated to specific underlying somatic 40 
mutations. Correct appreciation of differences in steroid profiling between aldosterone producing 41 
adenomas and bilateral adrenal hyperplasia may not only contribute to a better understanding of 42 
the pathogenesis of primary aldosteronism but may also be helpful for future subtyping of primary 43 
aldosteronism. 44 
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 3 
Introduction 51 
Steroid hormones produced in the adrenal cortex play a pivotal role in human physiology and in 52 
pathophysiology of adrenocortical disease. Histologically, the adrenal cortex can be divided into 53 
three layers, the zona glomerulosa (ZG), the zona fasciculata (ZF) and the zona reticularis (ZR), 54 
producing mineralocorticoids, glucocorticoids and androgens [1]. Aldosterone as a major 55 
mineralocorticoid, is synthesized in the ZG,  and plays a crucial role in the regulation of 56 
electrolyte and fluid homeostasis [2, 3]. 57 
11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) determine the essential 58 
steps in the synthesis of cortisol and aldosterone (Fig. 1). It was previously thought that the 59 
expression of these steroidogenic enzymes was linked to functional zonation of the adrenal cortex. 60 
However, recent studies using monoclonal antibodies against CYP11B1 and CYP11B2 showed 61 
that the distribution of both enzymes is complex and variable [4]. In the normal adrenal cortex, 62 
CYP11B1 immunopositive cells, although predominantly present in the ZF, appear to be localized 63 
in all cortical layers while CYP11B2 immunopositive cells are scattered or clustered as 64 
aldosterone producing cells in the subcapsular ZG [4]. These CYP11B2 positive cells, called 65 
aldosterone producing cells, may harbor somatic mutations that are known to be involved in 66 
aldosterone secretion [5]. 67 
An additional important steroidogenic enzyme for the synthesis of aldosterone and cortisol is 68 
the upstream 3β-hydroxysteroid dehydrogenase (HSD3B), which is expressed in both the ZG and 69 
ZF of the normal adrenal cortex and converts pregnenolone and 17OH-pregnenolone to 70 
progesterone and 17OH-progesterone respectively, thereby providing substrates for the synthesis 71 
of aldosterone and cortisol. HSD3B has two isoforms, HSD3B type 1 (HSD3B1) and HSD3B type 72 
2 (HSD3B2) which are expressed in the ZG and ZF, respectively [6].       73 
Dysfunctional mechanisms controlling aldosterone secretion may lead to a syndrome of excess 74 
aldosterone production called primary aldosteronism (PA). This syndrome is mainly due to two 75 
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subtypes: 1. aldosterone producing adenoma (APA) and 2. bilateral adrenal hyperplasia (BAH) [7, 76 
8]. The clinical features in patients with APAs are usually more severe than those with BAH 77 
because aldosterone production by APAs is usually more pronounced than in BAH. Except for 78 
aldosterone, tumoral production of other adrenal steroids may occur in both APAs and BAH as 79 
outlined below. 80 
Despite our current knowledge of the pathophysiology of PA, the biochemical differentiation 81 
between both subtypes of PA remains challenging. Therefore, a better understanding of the 82 
pathogenic mechanisms underlying these subtypes and a better identification of novel biomarkers 83 
such as specific steroids or steroid patterns may be helpful in the diagnosis and future treatment of 84 
PA. This paper reviews the specific patterns of steroid production in APAs but first summarizes 85 
the enzymes controlling steroid production in patients with APA, taking into account the recently 86 
discovered underlying mutational changes in these tumors. 87 
 88 
Steroidogenic enzyme expression in APAs 89 
Most APAs consist of tumor cells that resemble the mineralocorticoid producing cells of the ZG 90 
while BAH is characterized by bilateral hyperplasia of the adrenal ZG. However, many adrenals 91 
with an APA may have a hyperplastic zone while many adrenals with BAH may have nodular 92 
hyperplasia with nodules dispersed throughout the ZF [9, 10]. These APAs produce aldosterone as 93 
a major compound but also other steroids with mineralocorticoid effects. In addition, the disrupted 94 
functional zonation of the APAs may result in cross-utilization of substrates, thus contributing to 95 
an increased production of the hybrid steroids 18-oxocortisol (18-oxoF) and 18-hydroxycortisol 96 
(18-OHF) [11, 12] (Fig 1). 97 
In patients with APAs, CYP11B2 mRNA but not CYP11B1 mRNA levels were higher than in 98 
non-functional adenomas [13]. Localization studies using monoclonal antibodies against 99 
CYP11B1 and CYP11B2 showed that CYP11B1 immunoreactivity was diffusely dispersed with 100 
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CYP11B2 heterogenously spotted throughout the adenomas and barely detectable in the adjacent 101 
non-adenomatous tissue [14]. Semiquantitative assessment of CYP11B2 immunostaining of APAs 102 
using different scoring systems resulted in variable results [15]. Taking into account the size of the 103 
adenoma, several studies established a positive relationship between the CYP11B2 staining score 104 
and plasma or urinary aldosterone levels [10, 16, 17]. In contrast, Nakamura et al. could not 105 
establish a stronger immunoreactivity of CYP11B2 than in normal adrenal glands although it was 106 
higher in the APA than in the adjacent hyperplastic tissue [14]. In addition to these findings, 107 
microarray based gene expression analysis showed that the expression of CYP11B2 in APAs was 108 
considerably higher than the ZG of adjacent adrenal tissue [18].  109 
Localization studies of HSD3B1 and HSD3B2 in APAs showed that HSD3B2 mRNA was 110 
more abundantly present in APAs than HSD3B1 mRNA and yet it was HSD3B1 mRNA that was 111 
correlated with CYP11B2 mRNA [19]. Immunohistochemical studies also documented the 112 
presence of HSD3B2 immunopositive cells but again it was HSD3B1 expression that was 113 
correlated with that of CYP11B2. Both HSD3B1 and CYP11B2 are co-localized in the same APA 114 
cells, thus suggesting that HSD3B1 may also be involved in the production of aldosterone in 115 
APAs.  116 
The hyperplastic ZG of BAH demonstrates that HSD3B1 immunoreactivity is markedly 117 
increased and this may provide an explanation for the increased aldosterone production by the 118 
hyperplastic tissue in patients with BAH. Doi et al. have shown that BAH expresses HSD3B1 but 119 
not HSD3B2 suggesting that in contrast to APAs, where HSD3B2 is also associated with 120 
increased aldosterone production, HSD3B1 is responsible for the autonomous production of 121 
aldosterone in BAH [20, 21].  122 
Sakuma et al. have proposed to take diagnostic advantage of the high HSD3B2 in APAs by 123 
using a low CYP17/HSD3B2 ratio combined with a high expression of CYP11B2 as a biomarker 124 
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for the diagnosis of APA [13]. However, additional research is required to establish the benefits of 125 
this marker for diagnostic purposes.  126 
All these data suggest that based on their expression and function in steroidogenesis,  127 
CYP11B1, CYP11B2 and HSD3B may not only play an important role in the overproduction of 128 
aldosterone in APA but also of other steroids. An additional question is if and how the expression 129 
of steroidogenic enzymes in APAs is related to the different underlying somatic mutations in the 130 
genes that have been identified over the last few years in patients with APAs including, KCNJ5, 131 
ATP1A1, ATP2B3, CACNA1D [22]. These genes encode for the G-protein-activated inward 132 
rectifier potassium channel 4 (GIRK4), sodium-potassium transporting ATPase subunit α1 133 
(ATP1A1), plasma membrane calcium ATPase, type  3 (PMCA3) and the calcium  channel, 134 
voltage-dependent, L-type alpha 1d subunit (Cav1.3), respectively. Mutations in KCNJ5 have been 135 
demonstrated to be most prevalent in APA (38%), followed by CACNA1D (9.3%), and ATP1A1 136 
(5.3%) and ATP2B3 (1.7%) [23-26]. Irrespective of the gene affected, all somatic APA mutations 137 
lead to an activation of CYP11B2 gene transcription and enhanced aldosterone synthesis. 138 
APAs containing a mutation in KCNJ5 consist mainly of ZF-like cells, whereas adenomas with a 139 
mutation in ATP1A1 and CACNA1D have been demonstrated to consist of ZG-like cells [27, 28]. 140 
Williams et al. demonstrated that APAs with ATP1A1 and ATP2B3 mutations display increased 141 
CYP11B2 expression compared to those with KCNJ5 or no known mutations [26]. Monticone et 142 
al. demonstrated that ZG-like adenomas with ATP1A1, ATP2B3 and CACNA1D mutations were 143 
characterized by an increased expression of CYP11B2, while ZF-like APAs with KCNJ5 144 
mutations mainly expressed CYP11B1 [16]. This may account for differences in distinctive steroid 145 
profiles between APA patients harboring different mutations [29]. Dekkers et al. showed that 146 
KCNJ5 mutations were also associated with high CYP11B2 expression, present in both single 147 
adenomas, and nodular hyperplasia, while mutations in ATP2B3, and ATP1A1 and CACNA1D 148 
were solely found in single adenomas, and nodular hyperplasia, respectively [30].  149 
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 150 
Steroidogenesis in APA 151 
Qualitative measurements of the enzymatic pathways involved in the production of aldosterone 152 
and other steroids in APAs is nowadays addressed by modern immunohistochemical techniques 153 
applied to representative tissue slices of adenomas or hyperplastic tissue. Quantitative production 154 
of steroids, including aldosterone by adenomas or hyperplasia has been assessed at multiple levels: 155 
in adenoma or hyperplastic tissue itself, in peripheral venous blood samples, in urine, and in 156 
adrenal venous blood samples. Theoretically, it would be expected that with very sensitive, 157 
specific and reliable techniques, measurements of steroids in the tissue itself together with 158 
immunohistochemical studies on steroidogenic enzyme expression would be the best way to 159 
define the steroid profiles in APAs and BAH. Based on the relative expression levels of CYP11B1 160 
and CYP11B2 in the context of the disordered functional zonation of APAs, the direct precursors 161 
of aldosterone could possibly be affected in patients with these tumors. 162 
Adenoma tissue 163 
The first studies that reported the aldosterone and steroid content of APAs date back over 50 164 
years. To determine the steroid content and profile in APAs, surgically removed adenomas from 165 
patients with typical characteristics of PA, including hypertension and hypokalemia, were 166 
investigated. Once dissected, aldosterone and other steroids were extracted from adrenocortical 167 
tumors and normal adjacent adrenal gland tissue and separated by chromatography.  168 
In an early study, Biglieri et al. showed that, although the cortisol content of APA tissue was 169 
normal, these tumors had a nearly 3-fold elevated content of corticosterone (B) and 170 
desoxycorticosterone (DOC) while 11-deoxycortisol was minimally elevated compared to normal 171 
adrenal glands [31]. In some patients the B secretion rate was also elevated. Similar findings were 172 
described by Louis and Conn [32] and later by Kaplan et al. who demonstrated that APAs not only 173 
displayed higher aldosterone levels but also higher B levels compared to normal adrenal glands 174 
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and to adenomas in normotensive and primary hypertensive patients [33]. In vitro data on steroid 175 
production, obtained after incubating tissue slices from APAs showed that basal levels of B, DOC, 176 
and 18-hydroxycorticosterone (18-OHB), were at least two-fold higher in supernatants from APA 177 
than from adrenals of control patients [34]. These compounds have marked mineralocorticoid and 178 
blood pressure elevating activities. Finally, previous in vitro studies reported that both APAs and 179 
hyperplastic tissues were capable of secreting other compounds with mineralocorticoid and 180 
hypertensive properties in supernatants such as 19-nor-aldosterone (19-nor-aldo), 18-hydroxy-19-181 
nor-corticosterone (18-OH-19-nor-B) and 18,19-dihydroxycorticosterone (18,19(OH)2-B) [35]. 182 
The biological significance of these compounds in patients with PA is not well known but is 183 
probably limited. 184 
Peripheral venous plasma 185 
Previous in vitro data were confirmed by elevations in B, DOC, 18-OHB and 18-OHDOC in 186 
peripheral plasma vein samples from PA patients as compared to normal adrenal glands [34].  187 
Most in vivo studies have examined steroid concentrations in peripheral venous plasma to 188 
investigate steroid production by APAs while some studies used urine assays to analyze 189 
steroidogenesis in PA patients [36-40]. Earlier studies have mainly used immunoassays to 190 
quantify steroids while more recently liquid chromatography tandem mass spectrometry methods 191 
have been used. The latter have a better accuracy for steroid measurements than immunoassays 192 
[41-43].  193 
Ulick et al. were the first to recognize the unique urinary steroidogenic profile in patients with 194 
PA [11, 40].  The urinary excretion of the hybrid steroids 18-oxoF and 18-OHF were elevated in 195 
patients with APAs in contrast to those with BAH. This was later confirmed by Mulatero et al. 196 
who also found significantly higher plasma and urinary levels of these hybrid steroids in patients 197 
with APAs than with BAH [39]. The same applied for serum 18-OHB. Mosso et al. could confirm 198 
that plasma 18-OHF levels were not increased in patients with BAH, thus this is also in line with 199 
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previous studies [44]. A very recent study of Satoh et al. also demonstrated that plasma 18-oxoF 200 
and 18-OHF were nearly 10-fold and 2-fold elevated respectively in patients with APAs compared 201 
to BAH [45]. Of particular clinical relevance was their finding that peripheral plasma 18-oxoF was 202 
useful to discriminate APA from BAH patients.  203 
Adrenal venous plasma 204 
Adrenal venous sampling is nowadays considered the reference method to determine whether 205 
excess aldosterone production in PA patients is unilateral (usually APA) or bilateral (usually 206 
BAH). The plasma concentrations of aldosterone and other steroids in adrenal venous blood are 207 
considered to be a better reflection of their production by the adrenal glands than the peripheral 208 
vein plasma concentrations. Most recent reports on steroid quantification in adrenal venous plasma 209 
of patients with PA have used mass spectrometry [43, 46-48].  210 
Several studies have also addressed steroids other than aldosterone, such as 18-OHB and the 211 
two hybrid steroids 18-oxoF and 18-OHF [46-48]. Auchus and co-workers showed that, similar to 212 
aldosterone, adrenal vein plasma concentrations of 18-OHB were much higher in the vein draining 213 
from the diseased gland compared to that draining from the non-diseased contralateral gland [46]. 214 
However, 18-OHB was inferior to aldosterone for assessing the lateralization of aldosterone 215 
excess.  216 
Nakamura et al. demonstrated in a small study that 18-oxoF levels were elevated in adrenal 217 
venous samples from APAs as compared to BAH [47]. Furthermore, the adrenal vein ratio of 18-218 
oxoF/cortisol was helpful in discriminating APA from BAH. In a later study, the same authors 219 
showed that 18-oxoF concentrations were lower in the contralateral vein draining from the non-220 
diseased gland than the vein draining from the APA, thus illustrating that 18-oxoF was suppressed 221 
as might be expected [48]. The same group of investigators also examined the adrenal vein 222 
concentrations of 9 unconjugated C19 steroids, estrone, and estradiol. The most pronounced 223 
elevations in APA were found for 11�-hydroxyandrostenedione (11OHA), 224 
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dehydroepiandrosterone (DHEA) and androstenedione (A4) while active androgens such as 225 
testosterone were produced to a lesser degree [49]. 226 
 227 
Conclusion  228 
Studies using adenoma tissue, urine, peripheral and adrenal vein plasma have consistently shown 229 
that APAs in PA patients produce increased amounts of B, DOC, 18-OHB, 18-oxoF and 18-OHF 230 
in addition to the excess production of aldosterone. This specific pattern of increased steroid 231 
production by APAs may be explained by the dysregulated functional zonation of the enzymes 232 
involved in steroid synthesis (CYP11B1, CYP11B2 and HSD3B) in APAs. Underlying genetic 233 
mutations associated with different subtypes of PA may play an important role in the functional 234 
expression of these enzymes but this is still incompletely understood. It is also not fully clear 235 
whether this specific steroid profile associated with APAs will be of use for subtyping PA. With 236 
the advent of the more sensitive and specific mass spectrometry for measuring steroids, peripheral 237 
steroid biomarkers may prove to have a potential role in differentiating between BAH and APA. 238 
Prospective studies in large numbers of patients with different subtypes of PA are needed to 239 
validate the utility of steroids other than aldosterone for subtyping different forms of PA.  240 
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Figure 1. Mineralocorticoid and glucocorticoid synthesis in the human adrenal gland.  255 
Cholesterol side chain cleavage enzyme (CYP11A); 3β-hydroxysteroid dehydrogenase 256 
(HSD3B2); 17α-hydroxylase (CYP17A1); 21-hydroxylase (CYP21), 11β-hydroxylase 257 
(CYP11B1), aldosterone synthase (CYP11B2).  258 
The hybrid steroids 18-hydroxycortisol and 18-oxocortisol are mainly produced after conversion 259 
of 11-deoxycortisol by aldosterone synthase (CYP11B2). The 18-hydroxycortisol can also be 260 
produced from cortisol by aldosterone synthase (CYP11B2) but this pathway is much less 261 
effective (indicated by the dashed line). 262 
 263 
 264 
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